Exosomes From Adipose-Derived Mesenchymal Stem Cells: A New Prospective Therapy of Diabetic Foot Ulcer.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Diabetic foot ulcer (DFU) is one of the most severe complications of diabetes, characterized by high rates of morbidity, disability, and mortality. Current treatment modalities for DFU primarily include surgical debridement, negative-pressure wound therapy, and anti-infection measures. However, these approaches are limited by prolonged treatment duration, high costs, and suboptimal therapeutic outcomes. Adipose-derived mesenchymal stem cells (ADMSCs) have garnered significant attention in wound repair and tissue regeneration due to their ability to secrete a variety of cytokines involved in the healing process. Exosomes, as key mediators of the paracrine effects underlying the therapeutic benefits of ADMSCs, are emerging as promising agents for wound repair. As a novel therapeutic strategy, exosomes have been increasingly investigated for the treatment of DFU. In this review, we summarize the applications and therapeutic potential of ADMSC-exosomes in DFU, aiming to provide a valuable reference for its clinical management.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.